US/UK/Canada

Share

Contacts

  • Catharina Johansson

    CFO, IR & Communications


    Medicon Village 223 81 Lund Sweden
    +46 (0)46-275 62 21
    http://www.abliva.com
  • Abliva
    +46 (0)46 275 62 20
    • Pick a time period -
    Tags ( Active)

    NeuroVive Pharmaceutical AB (publ): Report from AGM

    NeuroVive Pharmaceutical AB (publ) held its Annual General Meeting (AGM) yesterday, 28 April 2016. A summary of the resolutions follows. All resolutions were passed with the required majority.Adoption of Income Statement, Balance Sheet, Consolidated Income Statement, Consolidated Balance Sheet and appropriation of profit and dividendThe Meeting resolved to adopt the presented Income Statement and Balance Sheet, and the Consolidated Income Statement and Consolidated Balance Sheet. The Meeting also resolved to appropriate the company’s profit or loss in accordance with the Board of

    NeuroVive’s R&D Team to Present Research Progress at Mitochondrial Medicine Conference

    NeuroVive Pharmaceutical AB (publ), the pioneers in mitochondrial medicine, will present important research findings together with researchers at Lund University in three scientific poster presentations at the conference entitled “Mitochondrial Medicine: Developing New Treatments for Mitochondrial Disease” being held 4-6 May 2016 in Cambridge, United Kingdom.The three scientific contributions submitted by the NeuroVive and Lund University research team have been accepted for poster presentation at the upcoming mitochondrial conference where global mitochondrial experts will be gathered. The

    NeuroVive starts preclinical TBI program in collaboration with PENN

    NeuroVive Pharmaceutical AB (publ), the pioneers in mitochondrial medicine, announces the start of the first study in the preclinical program in traumatic brain injury (TBI) which is being done in collaboration with the University of Pennsylvania (PENN).The TBI preclinical research program includes 3 different studies evaluating the protective effect of NeuroSTAT® in a TBI experimental model. TBI is an important unsolved problem in the medical field: nerve cell protection following moderate to severe brain trauma. There currently exist no approved treatments for this medical problem

    NeuroVive: large shareholder to participate in the rights issue

    NeuroVive Pharmaceutical AB (publ) announces that Baulos Capital Belgium SA, one of the largest shareholders, intends to participate in the upcoming rights issue.Fredrik Olsson (Baulos Capital) has informed the NeuroVive board of Baulos Capital's intention to subscribe for shares in NeuroVive's rights issue with a subscription period between April 18 - May 2, 2016. The commitment means a subscription of at least 75,000 units to the rights issue subscription price of 42 SEK, corresponding to 3.15 MSEK. Baulos Capital has also agreed to sell off unexercised warrants outside of the stock

    NeuroVive strengthens its organization with the recruitment of Cecilia Hofvander as IR and Communications Director

    NeuroVive Pharmaceutical AB (publ), the mitochondrial medicine company, announces that it has recruited Cecilia Hofvander as Investor Relations and Communications Director effective from 1 June 2016 in order to strengthen the company’s communication resources.Cecilia Hofvander joins NeuroVive from Active Biotech AB where she has worked for 15 years, the last eight as Assistant Director Investor Relations & Business Development. She holds a B.Sc in Chemistry and Molecular Biology from Lund University and has completed the Communication Executive Program at the Stockholm School of Economics.

    Notice of extraordinary general meeting in NeuroVive Pharmaceutical AB (publ)

    The shareholders in NeuroVive Pharmaceutical AB (publ) reg. no. 556595-6538  (the “Company”) are hereby convened to the extraordinary general meeting, held at 10.00 a.m. on Thursday, 31 March 2016 at Grand Hotel Lund, Bantorget 1 in Lund, Sweden, with admission for registration from 9.30 a.m.Entitlement to participate and notification Shareholders who wish to participate at the extraordinary general meeting must: · be included in the share register maintained by Euroclear Sweden AB on Wednesday 23 March 2016, and · notify the Company in writing by no later than Wednesday 23 March

    NeuroVive resolves on rights issue totaling approximately SEK 94.4 million for continued development of the project portfolio

    On 28 February 2016, The Board of Directors of NeuroVive Pharmaceutical AB (publ) (“NeuroVive” or ”the Company”) decided to carry out a new issue of shares and warrants (units) with preferential rights for existing shareholders (the “New Issue”). The resolution is subject to approval by the forthcoming Extraordinary General Meeting. Upon full subscription of the New Issue, the Company will raise approximately SEK 94.4 m before issue expenses. Full exercise of the warrants will raise at least a further SEK 32.6 million for the Company. The proceeds from the New Issue will be used for NeuroVive’

    Board Selects New CEO Erik Kinnman to Lead NeuroVive

    NeuroVive Pharmaceutical AB (publ) board of directors is pleased to announce that it has selected Erik Kinnman as NeuroVive’s Chief Executive Officer (CEO). Erik Kinnman will assume the new role on the 14th March 2016, leaving Chief Medical Officer (CMO) and Chief Operating Officer (COO) roles within his own consultancy business.Erik Kinnman is a seasoned life science executive with broad experience and understanding from the industry across a variety of businesses and functions. He has held a number of senior leadership positions in biopharmaceutical companies such as AstraZeneca and Sobi.

    NeuroVive announces departure of CEO and appointment of Jan Nilsson as interim CEO

    NeuroVive Pharmaceutical AB (publ), the mitochondrial medicine company, announces a change in leadership of the company.  Effective today, Mikael Brönnegård will no longer serve as Chief Executive Officer. The Board is pleased to announce that NeuroVive’s COO Jan Nilsson, who has extensive experience at senior levels within international pharmaceutical companies, will take over as interim CEO.The recruitment process to find a successor has begun and the company’s COO Jan Nilsson will head up the company in the role of interim CEO in the period until a new CEO is appointed by the Board of

    NeuroVive share upgraded on OTC market in US

    NeuroVive Pharmaceutical AB (publ), the mitochondrial medicine company, has announced that the company’s share has been upgraded from trading on the OTC Grey Market to OTC Pink in the US. The upgrade implies increased accessibility and transparency, and improves the potential to attract interest from US investors. This is in line with the company’s strategy to increase its presence in the US, the world’s largest pharmaceuticals market.Since March 2014, US investors have been able to trade electronically in the NeuroVive share in USD on the OTC Grey Market without requiring a Swedish broker

    NeuroVive announces the intention to raise additional capital through a private placement

    NeuroVive Pharmaceutical AB (publ) (”NeuroVive” or the “Company”, OMX:NVP) today announces that the Company intends to raise new equity through a private placement directed towards qualified institutional investors. The Company intends to effect the private placement at a share volume and a price per share to be determined through an accelerated bookbuilding process. The Board of Directors will disapply the preferential subscription rights of existing shareholders in connection with the intended capital increase, which will take place within the limits of the authorization from the Annual

    Published data indicates protective effect of cyclosporine in patients with stroke

    The results of a clinical phase II study indicating that cyclosporine counteracts brain injury in a subset of stroke patients undergoing thrombolysis has been published in an article co-authored by one of NeuroVive’s research partners, professor Michel Ovize of Hospices Civils de Lyon (HCL).The French phase II study investigated the neuroprotective effect of cyclosporine, the active substance in NeuroVive’s product NeuroSTAT®, in 127 stroke patients who also received thrombolysis treatment (to reinstate the occluded blood flow) in the period 2009-2013. For all patients included in the study,

    First patient enrolled in clinical phase II study for kidney protection during heart surgery

    NeuroVive Pharmaceutical AB (publ), the mitochondrial medicine company, announces that the first patient has been enrolled in a clinical phase II study for acute kidney injury using the company’s product CicloMulsion®. The study, known as CiPRICS, is being conducted by Skåne University Hospital and will evaluate the product’s ability to prevent acute kidney injury during heart surgery.The CiPRICS (Ciclosporin to Protect Renal function In Cardiac Surgery) study is a double-blind, randomized and placebo-controlled clinical phase II study. The study will include a total of 150 patients at the

    Clinical Phase II study with NeuroSTAT® for traumatic brain injury passes safety evaluation

    NeuroVive Pharmaceutical AB (publ), the mitochondrial medicine company, announces that the independent safety committee has endorsed moving on to the next dose level without any safety issues, following the treatment of 10 of 20 patients in the ongoing clinical Phase IIa study for traumatic brain injury with the company’s drug candidate NeuroSTAT®. Consequently, the study will continue as planned and move on to the next dosage group.The ongoing CHIC study (Copenhagen Head Injury Ciclosporin Study) is an open-label, non-comparative clinical Phase IIa study enrolling a total of 20 patients

    NeuroVive establishes subsidiary in Lyon and extends collaboration with HCL

    NeuroVive Pharmaceutical AB (publ), the mitochondrial medicine company, has established a subsidiary in Lyon, France. The establishment is part of a process of extending its ongoing collaboration with Hospices Civils de Lyon (HCL) and Professor Michel Ovize (the OPeRa program) to include drug development for the treatment of stroke. The creation of a legal entity in France also coincides with preparations for the potential commercialization of the company’s product CicloMulsion®.NeuroVive is party to an ongoing collaboration with Hospices Civils de Lyon (HCL) and Professor Michel Ovize (the

    Development of NVP014 for the treatment of stroke enters new phase in collaboration with Isomerase Therapeutics

    NeuroVive Pharmaceutical AB (publ), the mitochondrial medicine company, has announced that the company’s development project NVP014 for the treatment of ischemic stroke is entering a new phase in collaboration with UK partner Isomerase Therapeutics. The former collaboration with to-BBB of the Netherlands concluded at the end of 2014 and on the basis of the results obtained, NeuroVive is now developing new molecules and a more effective method for penetrating the blood-brain barrier.NeuroVive’s collaboration with to-BBB Technologies B.V. of the Netherlands on the development of NVP014 for

    Merger between OnCore and Tekmira includes development of NVP018 for the treatment of Hepatitis B

    US biotechnology company OnCore Biopharma, Inc. (OnCore), which has licensed NeuroVive’s drug candidate NVP018 for the treatment of chronic Hepatitis B virus infection (HBV), has agreed to merge with Canadian listed RNAi therapeutics company Tekmira Pharmaceuticals Corporation (Tekmira). OnCore would continue as a subsidiary of Tekmira, and the licensing agreement for NVP018 between NeuroVive and OnCore will remain in force following the merger as the combined company continues to work in the HBV area.OnCore  and Tekmira  announced

    NeuroVive signs USD 150 m agreement with OnCore BioPharma for the outlicensing of NVP018 for the treatment of chronic Hepatitis B virus infection

    NeuroVive Pharmaceutial AB, a leading mitochondrial medicine company, has signed an exclusive global outlicensing agreement with the US biotechnology company OnCore BioPharma, Inc. related to the development and commercialization of NeuroVive’s drug candidate NVP018 for oral treatment of chronic Hepatitis B Virus (HBV) infection. The agreement can give NeuroVive in total $150 million in conditional milestone payments plus royalties on future drug sales.“After extensive discussions with a number of leading pharmaceutical companies, I am delighted to announce that we have signed this

    Enrollment to phase II study on NeuroSTAT® continues

    Enrollment to the ongoing clinical phase IIa study with NeuroVive’s drug candidate NeuroSTAT® for treating patients with severe traumatic brain injury (TBI) is continuing, and another two patients have been enrolled. Accordingly, at present, seven of a total of 20 patients have been enrolled in the study.The enrollment of new patients to the study has taken somewhat longer time than scheduled, but NeuroVive assumes that the ten patients to be treated with a lower dose will have been enrolled by year-end, or during Q1 2015 at the latest. Subsequently, the plan is to conduct interim analysis

    NeuroVive signs new agreement with Hospices Civils de Lyon

    NeuroVive is extending its collaboration with Hospices Civils de Lyon (HCL) and Professor Ovize, which broadens the scope of NeuroVive’s cardiovascular business area and creates the right conditions for the company to retain its leading position in mitochondrial medicine. The new collaboration agreement, designated OPeRA (Organ Protection & Replacement Institute), includes pre-clinical research and development programs as well as clinical phase II programs, providing NeuroVive with access to medical technology and patient groups for the evaluation of its drug candidates.NeuroVive began its

    There are no items matching the current filter
    There are no more items matching the current filter
    Back to top

    Subscribe